Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
about
Glycaemic Effects of Non-statin Lipid-Lowering TherapiesMendelian randomization in cardiometabolic disease: challenges in evaluating causality.PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Differential sex effects of systolic blood pressure and low-density lipoprotein cholesterol on type 2 diabetes: Life course data from the Bogalusa Heart Study.Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.Statins and New-Onset Diabetes Mellitus: LDL Receptor May Provide a Key Link.Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects.Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis.PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.10 Years of GWAS Discovery: Biology, Function, and Translation.Mendelian randomisation in cardiovascular research: an introduction for clinicians.Human genetic insights into lipoproteins and risk of cardiometabolic disease.Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order Amish.Alirocumab for the treatment of hypercholesterolaemia.Bococizumab for the treatment of hypercholesterolaemia.PCSK9 inhibition: the dawn of a new age in cholesterol lowering?Diabetes Secondary to Treatment with Statins.PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.Mendelian randomization for investigating causal roles of biomarkers in multifactorial health outcomes: a lesson from studies on liver biomarkers.Statin Use and the Risk of Type 2 Diabetes Mellitus in Children and Adolescents.Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events.Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease.PCSK9 and carbohydrate metabolism: A double-edged sword.A combination of plasma phospholipid fatty acids and its association with incidence of type 2 diabetes: The EPIC-InterAct case-cohort study.Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.Exome-wide association study of plasma lipids in >300,000 individuals.A Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, Independent of Recommended Macronutrient Replacement and Time Point of Consumption: a Prospective, Randomized, Controlled Trial.Genetic Variants of the Receptor for Advanced Glycation End-products in Susceptibility to Type 2 Diabetes Mellitus in Primary Hypertensive Patients.Leveraging Human Genetics to Understand the Relation of LDL Cholesterol with Type 2 Diabetes.The small dense LDL particle/large buoyant LDL particle ratio is associated with glucose metabolic status in pregnancy.The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis.Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies.Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities.The obesity epidemic and rising diabetes incidence in a low-income racially diverse southern US cohort.Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure.Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
P2860
Q28070152-D677A599-4A37-41C1-876F-4FE835D6C3EBQ30234302-DF8AE6D3-E161-46AF-98D9-E4F05BE04A43Q30234612-1F5F1861-47E0-48C5-9D8C-6F5A88778915Q31166655-A18B848D-005D-4A6C-AEE2-1BDD326ABF5BQ33623532-2EF213BF-A3B9-4BB3-87B7-89703C310C58Q33730396-7DFD50FF-D5E8-4DA8-A76A-5E0A245B5FD2Q33790331-57367E83-1562-488B-B4D9-741E5646DD6FQ33831184-EDA1BCB0-4CBF-44A2-BB25-0C0B707EC107Q36206751-D37FF1A2-BEBC-4046-954E-AF83F290EAABQ37607330-0A4B0722-79B1-4F8B-9830-ADD1B54152D5Q38689236-5AACE3DF-157A-4AF9-AC88-06E406CC6BCAQ38735373-79822403-F478-4B98-8615-6F88B5A98E15Q38774074-1AD75F9D-5922-4F34-8798-57D358CC47CEQ38827776-69E84508-37A3-4B88-97B8-93A79C2E83CBQ38843982-B24D7188-32B7-4A1C-B02B-CAF500E52DF1Q39035931-A4B013B1-F1E0-4ADE-A273-496DB5008CFEQ39057046-D3C03FB6-AD08-4BC9-80B2-919B29ECEE07Q39117136-5BEDF650-C8F0-4611-B043-DCFD5136272FQ39453691-A9A3BA66-F7D5-47B5-9293-DB716BEC6993Q40215028-C9CA96CC-4AD0-4BA4-B6D8-532961890EC0Q40321293-B7F9C96C-8CC7-4F17-9BB3-EEF0298A83A4Q41190859-DF5766B5-BA53-4A35-845D-12D37BA70534Q42244280-CF008D93-132C-4D3E-A768-35412630295AQ42333207-CCB8B87E-4C50-4058-B9E4-43D453F96A17Q42705334-A70F31F1-E2DD-436C-BD85-424E21ED96D7Q44847105-01FC2F46-F9CF-4F37-ADB0-5043E9FC53E8Q45071322-4E323A9A-60BC-4C87-BBF7-044204FEC192Q45985992-E676D575-A3D3-45D3-B95E-0D818323FAB9Q47093706-9B407015-AC18-47C9-95AD-C50AF239B52EQ47101294-874975B2-BEB3-4F3C-9ACC-D589F78816F4Q47138342-D5D9514F-4D1B-4B3A-990A-0F860B3BF555Q47405486-731AAD89-CE7B-45CA-AC6B-93842A6A3C6AQ47419614-FAEC05AE-C5A0-4CEB-8F57-E2440C6FCA93Q47650146-6136E7DB-1B79-4C9E-919C-4A142D55B775Q47726362-83800431-E66D-4670-8113-0F6F7B123876Q47776394-8A1EE138-07AD-4145-9E26-78E51AF386B5Q48258995-65CDA30B-B8C7-4E88-AC27-6976C9EDC9A0Q50047295-BE181205-B5DC-48F4-B3AE-A7C8467630C5Q52324964-78146981-AAA3-47FB-BA00-6D543132CE0EQ52721601-AEC5C90A-0189-443B-B94B-C0B262330651
P2860
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Association Between Low-Densit ...... e 2 Diabetes: A Meta-analysis.
@en
Association Between Low-Densit ...... e 2 Diabetes: A Meta-analysis.
@nl
type
label
Association Between Low-Densit ...... e 2 Diabetes: A Meta-analysis.
@en
Association Between Low-Densit ...... e 2 Diabetes: A Meta-analysis.
@nl
altLabel
Association Between Low-Densit ...... ts and Risk of Type 2 Diabetes
@en
prefLabel
Association Between Low-Densit ...... e 2 Diabetes: A Meta-analysis.
@en
Association Between Low-Densit ...... e 2 Diabetes: A Meta-analysis.
@nl
P2093
P2860
P50
P921
P356
P1476
Association Between Low-Densit ...... e 2 Diabetes: A Meta-analysis.
@en
P2093
Annemieke Mw Spijkerman
Beverley Balkau
Daphne L van der A
Elena C Salamanca
Isobel D Stewart
Jian'an Luan
John R B Perry
Jose-Ramón Quirós
Larraitz Arriola
Olov Rolandsson
P2860
P304
P356
10.1001/JAMA.2016.14568
P407
P50
P577
2016-10-01T00:00:00Z